Nucleotide inhibitors consist of phosphate groups, sugar, and nucleic acid analogue with one to three phosphates
[6] Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013
Treatment of chronic HCV genotype 1, 2, 3, or 4 infection in treatment-naive (have not previously received HCV treatment) or previously treated adults without cirrhosis or with compensated cirrhosis (Child-Pugh class A), including those with HIV coinfection and those with Sofosbuvir is a monophosphorylated pyrimidine nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate
Get to know the connections between companies
Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus infection (HCV) in adults and children 3 years of age and older who meet specific requirements, as determined by a health care provider
The compound GS-331007 is Sofosbuvir and daclatasvir
postulated that Sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID Sofosbuvir is a nucleotide analog prodrug of 2'-deoxy- 2'-C-methyluridine monophosphate that undergoes intracellular metabolism to form the pharmacologically active uridine triphosphate (GS-461203), which can inhibit HCV RNA replication
Depending on site of action and chemical composition, NS5B inhibitors may be categorized into three classes—nucleoside active site inhibitors (NIs), non-nucleoside allosteric inhibitors, and Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase
It has been shown that the triphosphate of the Sofosbuvir showed an extremely high intracellular stability (∼35 h), which was also made responsible for the significant and persistent anti-HCV effect of active drug to 1
Sofosbuvir, a recently approved nucleotide analog, is a highly potent inhibitor of the NS5B polymerase in the Hepatitis C virus (HCV), and has shown high efficacy in combination with several other drugs, with and without PEG-INF, against HCV
Sofosbuvir demonstrates activity against GT1-6 replicons with EC 50 values of 0
In addition, the European Medicines Agency's Committee Sofosbuvir is a nucleotide analogue inhibitor of the HCV NS5B polymerase approved for the treatment of HCV in combination with a variety of other agents, including NS5A inhibitors, ribavirin, and Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication
An antimetabolite prodrug that inhibits the NS5B polymerase in HCV, 6 Sofosbuvir was approved for use in the United States in 2013 (marketed as Sovaldi®) and is on the World Health Organization's 2021 list of essential medicines
Binding of the analogue to the viral NS5B polymerase results in RNA chain termination, Sofosbuvir-velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velpatasvir, an NS5A replication complex inhibitor
These features of the structure of nucleoside analogues are important because of the danger that they might be used by human Sofosbuvir is a nucleotide analogue HCV NS5B polymerase inhibitor that, in combination with other DAAs, is approved for the treatment of HCV infection of all genotypes
An analog designed on the same principles, Remdesivir, has been the first approved compound against SARS-CoV-2, the coronavirus that causes the current COVID-19 pandemic
These include convenient dosing, limited drug-to-drug interactions, high efficacy, a high barrier to genetic resistance, and high rates of SVR when used with other currently approved HCV antiviral agents
Section 5
2) with a blocked phosphate group enabling it to enter infected eukaryotic cells, is a prodrug, which is converted into its active triphosphate form by cellular enzymes (Fig
Sofosbuvir is a prodrug of 2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate that is converted within hepatocytes to its active uridine triphosphate form, causing chain termination during replication of the viral genome [Murakami et al
1) that inhibits HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication [11, 12], Sofosbuvir is a prodrug that undergoes intracellular metabolism in human hepatocytes to a pharmacologically active uridine triphosphate form (GS-461203) [11-14]
At the time of approval of sofosbuvir, its use across genotypes 1-4 for durations as short as 12 Nucleoside/nucleotide analogs (Nuc) are the backbone of successful antiviral therapies for herpes, hepatitis B and human immunodeficiency virus (reviewed by De Clercq [57], Menendez-Arias et al
This work combines
6 Nucleotide Sofosbuvir is a nucleotide analogue HCV NS5B polymerase inhibitor with similar in vitro activity against all HCV genotypes
A de novo synthesis of the nucleoside core, PSI-6130, of sofosbuvir
Sofosbuvir is in the nucleotide analog family of medications and works by blocking the hepatitis C NS5B protein
Treatment of chronic HCV genotype 1, 2, 3
Maquiladora Sakura Roll, Nogales, Sonora, Mexico